Results 181 to 190 of about 5,080 (193)

Lecanemab/methylprednisolone

Reactions Weekly
openaire   +1 more source

Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis

Ageing Research Reviews
Neyder Contreras
exaly  

Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center

journal of prevention of Alzheimer's disease, The
C B Shields
exaly  

Lecanemab’s benefits are too small and uncertain

BMJ
openaire   +4 more sources

Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence

Journal of Alzheimer's Disease
M B N Kouwenhoven, Don Eliseo Iii Lucero-Prisno, Rehab Emad Ashmawy   +2 more
exaly  

Lecanemab (▼Leqembi) for Alzheimer’s disease

Drug and Therapeutics Bulletin
openaire   +2 more sources

Profiling lecanemab as a treatment option for Alzheimer’s disease

Expert Review of Neurotherapeutics
George Grossberg, Emily Schiller
exaly  

Amyloid‐related imaging abnormalities in a woman with apolipoprotein E ε4 homozygotes treated with lecanemab for Alzheimer's disease

Clinical and Experimental Neuroimmunology
Kenjiro Ono, Moeko Noguchi-Shinohara
exaly  

Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease

journal of prevention of Alzheimer's disease, The
Steven Hersch, C P L H Chen, Amitabh Dash   +2 more
exaly  

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

British Journal of Clinical Pharmacology
Amy Bobbins, Elizabeth Lynn, Saad Shakir   +2 more
exaly